newsfilter
← Latest News
ACCESS Newswire·

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations